- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
- Publication Ethics
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Novel Research in Sciences
Abnormal Methylation Enzymes as the Bullseye of Targeted Cancer Therapies
-
Open or CloseMing C Liau* and Linda Liau Baker
CDA Therapeutics Inc, USA
*Corresponding author:Ming C Liau, CDA Therapeutics Inc, 3308 Sky Run Court, Missouri City, TX 77459, USA
Submission: April 16, 2021;Published: May 3, 2021
.jpg)
Abstract
Non-targeted cell killing is the choice of cancer therapy in the past, because it is the most effective strategy to stop the perpetual proliferation of cancer cells. Non-targeted cell killing includes cytotoxic chemotherapy and radiotherapy that aims to kill cells in replication indiscriminately. Non-targeted cell killing dominates cancer therapy for as long as one can remember, but cancer mortalities remain at old time high worldwide. Obviously, non-targeted cell killing is unable to save the majority of cancer patients.
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version